Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro
- PMID:11099780
- DOI: 10.1016/s0197-0186(00)00091-7
Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro
Abstract
The alternative routes of cleavage of the amyloid precursor protein (APP) result in the generation and secretion of both soluble APP and beta-amyloid, the latter being the main component of the amyloid deposits in the brains of individuals with Alzheimer's disease (AD). This study examined the question of whether acetylcholinesterase (AChE) inhibitors can alter the processing of APP and the level of protein kinase C (PKC) in primary rat basal forebrain cultures. Western blotting was used to test two AChE inhibitors (reversible and irreversible) for their ability to enhance the release of APP and PKC content. These inhibitors were ambenonium (AMB) and metrifonate (MTF), at different concentrations. A significant increase was found in the cell-associated APP level in a basal forebrain neuronal culture, and there was an elevation of the APP release into the medium. Increases were similarly observed in the PKC levels after AMB or MTF treatment. The results suggest that these AChE inhibitors promote the non-amyloidogenic route of APP processing, which may be due to their stimulatory effects on PKC. The PKC activation may enhance the alpha-secretase activity and consequently the production of the N-terminal APP. Since both a decreased level of APP secretion and a low activity and level of PKC may be involved in the pathogenesis of AD, it is concluded that the administration of AChE inhibitors to AD patients may facilitate the memory processes and exert a neuroprotective effect.
Similar articles
- In vitro effects of metrifonate on neuronal amyloid precursor protein processing and protein kinase C level.Pakaski M, Rakonczay Z, Fakla I, Papp H, Kasa P.Pakaski M, et al.Brain Res. 2000 Apr 28;863(1-2):266-70. doi: 10.1016/s0006-8993(00)02120-x.Brain Res. 2000.PMID:10773217
- Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695.Peng Y, Lee DY, Jiang L, Ma Z, Schachter SC, Lemere CA.Peng Y, et al.Neuroscience. 2007 Dec 5;150(2):386-95. doi: 10.1016/j.neuroscience.2007.09.022. Epub 2007 Sep 14.Neuroscience. 2007.PMID:17945434
- Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures.Lahiri DK, Farlow MR, Nurnberger JI Jr, Greig NH.Lahiri DK, et al.Ann N Y Acad Sci. 1997 Sep 26;826:416-21. doi: 10.1111/j.1749-6632.1997.tb48495.x.Ann N Y Acad Sci. 1997.PMID:9329715
- Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein.Pakaski M, Kasa P.Pakaski M, et al.Curr Drug Targets CNS Neurol Disord. 2003 Jun;2(3):163-71. doi: 10.2174/1568007033482869.Curr Drug Targets CNS Neurol Disord. 2003.PMID:12769797Review.
- Amyloid precursor protein processing in vivo--insights from a chemically-induced constitutive overactivation of protein kinase C in Guinea pig brain.Bigl V, Rossner S.Bigl V, et al.Curr Med Chem. 2003 May;10(10):871-82. doi: 10.2174/0929867033457692.Curr Med Chem. 2003.PMID:12678689Review.
Cited by
- Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease.Lahiri DK, Alley GM, Tweedie D, Chen D, Greig NH.Lahiri DK, et al.Neuromolecular Med. 2007;9(2):157-68. doi: 10.1007/BF02685889.Neuromolecular Med. 2007.PMID:17627035
- Design, synthesis and biological evaluation of edaravone derivatives bearing theN-benzyl pyridinium moiety as multifunctional anti-Alzheimer's agents.Zondagh LS, Malan SF, Joubert J.Zondagh LS, et al.J Enzyme Inhib Med Chem. 2020 Dec;35(1):1596-1605. doi: 10.1080/14756366.2020.1801673.J Enzyme Inhib Med Chem. 2020.PMID:32779503Free PMC article.
- Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?Giacobini E.Giacobini E.CNS Drugs. 2001;15(2):85-91. doi: 10.2165/00023210-200115020-00001.CNS Drugs. 2001.PMID:11460892Review.
- Cholinesterases: new roles in brain function and in Alzheimer's disease.Giacobini E.Giacobini E.Neurochem Res. 2003 Apr;28(3-4):515-22. doi: 10.1023/a:1022869222652.Neurochem Res. 2003.PMID:12675140Review.
- Molecular rationale for the pharmacological treatment of Alzheimer's disease.Zimmermann M, Gardoni F, Di Luca M.Zimmermann M, et al.Drugs Aging. 2005;22 Suppl 1:27-37. doi: 10.2165/00002512-200522001-00003.Drugs Aging. 2005.PMID:16506440Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous